$1.7 billion deal adds innovative interatrial shunt to J&J’s cardiovascular offerings.
Johnson & Johnson (NYSE: JNJ) has finalized its $1.7 billion acquisition of V-Wave, a developer of cardiovascular implant technology for heart failure patients. This acquisition builds on J&J’s initial investment in V-Wave in 2016 and aligns with its strategy to expand into high-growth cardiovascular markets.
Transformative Technology for Heart Failure
V-Wave’s Ventura interatrial shunt targets patients with heart failure and reduced ejection fraction (HFrEF), addressing an unmet need for over 800,000 U.S. patients annually. The minimally invasive device creates a shunt between the left and right atrium to reduce elevated left atrial pressure, potentially decreasing cardiovascular events and hospitalizations.
“This technology has the potential to be the first device of its kind to market,” said Tim Schmid, EVP and Worldwide Chair of J&J MedTech.
Building on Cardiovascular Leadership
J&J continues its aggressive expansion in cardiovascular care, following major acquisitions of Abiomed ($16.6B), Laminar ($400M), and Shockwave Medical ($13.1B). These strategic moves deepen relationships with cardiologists and enhance J&J’s presence in structural heart and heart failure treatments.
The V-Wave acquisition underscores J&J’s focus on transformative innovations that improve patient outcomes in cardiovascular care.
Follow MEDWIRE.AI for updates on MedTech acquisitions and innovations.
